Alice B Gottlieb Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

01/2008	Etanercept treatment for children and adolescents with plaque psoriasis.
01/2008	A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
06/2007	Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
05/2007	Mechanisms of action of etanercept in psoriasis.
05/2007	A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.
04/2007	An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.
01/2007	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
11/2006	Ability to develop rhus allergic contact dermatitis in a patient with psoriasis receiving etanercept.
10/2006	An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
10/2006	Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.
07/2006	Biologic therapies for psoriasis. A systematic review.
04/2006	Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
03/2006	Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
01/2006	Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
01/2006	New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
12/2005	Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.
08/2005	Treatment of palmoplantar psoriasis with intramuscular alefacept.
03/2005	Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
03/2005	Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.
12/2004	A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
12/2004	Alefacept is well tolerated in patients with chronic plaque psoriasis.
11/2004	Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
10/2004	Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
07/2004	Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.
04/2004	Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
01/2004	Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances.
01/2004	Etanercept for the treatment of psoriasis and psoriatic arthritis.
12/2003	A randomized trial of etanercept as monotherapy for psoriasis.
11/2003	Etanercept as monotherapy in patients with psoriasis.
11/2003	CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.
09/2003	Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation.
09/2003	Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis.
08/2003	Infliximab for psoriasis.
06/2003	Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.
06/2003	The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison.
05/2003	The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions.
05/2003	Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.
01/2003	Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
12/2002	TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis.
11/2002	Recombinantly engineered human proteins: transforming the treatment of psoriasis.
05/2002	Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

Articles by Research Topic

Disease

41	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2008 - 05/2002
4	Psoriatic Arthritis 01/2006 - 09/2003
2	Atopic Dermatitis (Atopic Eczema) 09/2005 - 08/2005
1	Sclerosis 10/2008
1	Facial Paralysis (Facial Palsy) 06/2008
1	Syphilis 06/2008
1	Benign Familial Pemphigus (Hailey Hailey Disease) 07/2007
1	Allergic Contact Dermatitis 11/2006
1	Arthritis (Polyarthritis) 01/2006
1	Mycosis Fungoides 07/2004
1	Acne Vulgaris 03/2004

Drug/Important Bio-Agent (IBA)

11	TNFR-Fc fusion protein (etanercept)FDA Link 01/2008 - 11/2003
7	efalizumab FDA Link 04/2006 - 05/2002
6	infliximab (Remicade)FDA Link 01/2007 - 01/2003
5	alefacept (Amevive)FDA Link 01/2008 - 11/2003
3	Interleukin-12 (IL 12)IBA 05/2007 - 12/2004
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2003 - 12/2002
2	pimecrolimus (Elidel)FDA Link 09/2005 - 11/2004
2	Clobetasol (Clobetasol Propionate)FDA LinkGeneric 07/2004 - 05/2003
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2008
1	imatinib (Gleevec)FDA Link 10/2008
1	Acitretin FDA Link 07/2007
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 04/2007
1	ChemokinesIBA 10/2006
1	CytokinesIBA 10/2006
1	Tacrolimus (Prograf)FDA Link 08/2005
1	adjuvant P40 (P 40)IBA 12/2004
1	galiximabIBA 04/2004
1	Cholestenone 5 alpha-Reductase (5 alpha-Reductase)IBA 03/2004
1	Prostaglandins A (PGA)IBA 06/2003
1	Proteins (Proteins, Gene)IBA 11/2002

Therapy/Procedure

2	Climatotherapy 07/2004 - 09/2003
1	Aftercare (After-Treatment) 06/2008
1	Biological Therapy 07/2006
1	Immunotherapy 01/2004